adolescents: recommendations from an international expert panel Diagnosis and management of acute myeloid leukemia in children and

[1]  H. Dombret,et al.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.

[2]  D. Reinhardt,et al.  Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report , 2012, Leukemia.

[3]  G. Kaspers.  Pediatric acute myeloid leukemia , 2012, Expert review of anticancer therapy.

[4]  G. Malaguarnera,et al.  Rasburicase for the treatment of tumor lysis in hematological malignancies , 2012, Expert review of hematology.

[5]  S. Raimondi,et al.  AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia , 2012, Cancer.

[6]  L. Leibovici,et al.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. , 2012, The Cochrane database of systematic reviews.

[7]  S. Devesa,et al.  Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. , 2012, Blood.

[8]  R. Arceci,et al.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. , 2011, Blood.

[9]  H. Döhner,et al.  Impact of genetic features on treatment decisions in AML. , 2011, Hematology. American Society of Hematology. Education Program.

[10]  D. Reinhardt,et al.  CNS irradiation in pediatric acute myleoid leukemia: Equal results by 12 or 18 Gy in studies AML‐BFM98 and 2004 , 2011, Pediatric blood & cancer.

[11]  R. Rosenquist,et al.  Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. , 2011, Blood.

[12]  H. Dombret,et al.  Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA) , 2011 .

[13]  C. Volteau,et al.  Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study , 2011 .

[14]  R. Hills,et al.  The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial , 2011 .

[15]  A. Teigler‐Schlegel,et al.  Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). , 2011, Blood.

[16]  K. Wheatley,et al.  Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial , 2011, British journal of haematology.

[17]  M. Heuser,et al.  Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML–BFM and DCOG study groups , 2011, Leukemia.

[18]  R. Pieters,et al.  Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia , 2011, Haematologica.

[19]  R. Pieters,et al.  NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. , 2011, Blood.

[20]  E. Vellenga,et al.  Original Articles Design and Methods Prognostic Impact of White Blood Cell Count in Intermediate Risk Acute Myeloid Leukemia: Relevance of Mutated Npm1 and Flt3-itd , 2022 .

[21]  P. Vyas,et al.  Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. , 2011, Blood.

[22]  S. Shurtleff,et al.  Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Raimondi,et al.  Leukemic mutations in the methylation‐associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group , 2011, Pediatric blood & cancer.

[24]  S. Bhatia.  Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up , 2011, Expert review of hematology.

[25]  Y. Lee,et al.  Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML , 2011, Chonnam medical journal.

[26]  K. Wagner,et al.  Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Döhner,et al.  Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein α from hematopoietic cells in a family with AML , 2011, Leukemia.

[28]  S. Raimondi,et al.  Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group , 2011, Leukemia.

[29]  R. Storb,et al.  Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement. , 2011, International journal of radiation oncology, biology, physics.

[30]  M. Teixeira,et al.  Acute megakaryoblastic leukemia with a four‐way variant translocation originating the RBM15–MKL1 fusion gene , 2011, Pediatric blood & cancer.

[31]  A. Órfão,et al.  Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10 , 2011, Leukemia.

[32]  E. Estey,et al.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Órfão,et al.  Mixed phenotype acute leukemia (MPAL): clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification Authors: , 2011 .

[34]  A. Groll,et al.  Invasive fungal infections in the pediatric population , 2011, Expert review of anti-infective therapy.

[35]  C. Niemeyer,et al.  Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study , 2011, Leukemia.

[36]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  C. Pui,et al.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Hills,et al.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Rob Pieters,et al.  Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia , 2011, Haematologica.

[40]  K. Jahnukainen,et al.  Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Pieters,et al.  KIAA1524: A novel MLL translocation partner in acute myeloid leukemia. , 2011, Leukemia research.

[42]  S. Kannan,et al.  Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. , 2011, Hematology/oncology and stem cell therapy.

[43]  R. Hills,et al.  Independent prognostic variables in acute myeloid leukaemia. , 2011, Blood reviews.

[44]  Joshua F. McMichael,et al.  DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.

[45]  D. Reinhardt,et al.  Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity , 2010 .

[46]  U. Creutzig,et al.  A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. , 2010, Blood.

[47]  A. Pession.  The open issue of central nervous system disease in pediatric acute myeloid leukemia , 2010, Pediatric blood & cancer.

[48]  D. Johnston,et al.  The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: A Children's Oncology Group study , 2010, Pediatric blood & cancer.

[49]  J. Dongen,et al.  Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol , 2010, Leukemia.

[50]  S. Orkin,et al.  Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. , 2010, Genes & development.

[51]  R. Pieters,et al.  Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. , 2010, European journal of cancer.

[52]  V. Cornelius,et al.  Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials , 2010, BMC Cancer.

[53]  D. Reinhardt,et al.  Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials , 2010, Leukemia.

[54]  E. van den Berg,et al.  Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  O. Haas,et al.  Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Elaine Coustan-Smith,et al.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.

[57]  T. Kalina,et al.  Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria , 2010, Haematologica.

[58]  D. Reinhardt,et al.  Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[60]  G. Henze,et al.  Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses , 2010, British journal of haematology.

[61]  R. Pieters,et al.  EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia , 2010, Leukemia.

[62]  M. Schrappe,et al.  Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations , 2010, British journal of haematology.

[63]  I. Bernstein,et al.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. , 2010, Blood.

[64]  F. Bessho,et al.  Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy , 2010, International journal of hematology.

[65]  Lingling Zhu,et al.  Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. , 2010, Blood.

[66]  D. Reinhardt,et al.  Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study , 2010, British journal of haematology.

[67]  R. Hills,et al.  Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[69]  S. Schnittger,et al.  Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. , 2010, Blood.

[70]  R. Egeler,et al.  High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study , 2010, Bone Marrow Transplantation.

[71]  J. Bennett,et al.  Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.

[72]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[73]  F. Appelbaum.  Optimising the conditioning regimen for acute myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.

[74]  R. Arceci,et al.  WT1 expression at diagnosis does not predict survival in pediatric aml: A report from the Children's Oncology Group , 2009, Pediatric blood & cancer.

[75]  L. Silverman,et al.  A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia , 2009, Leukemia.

[76]  A. Baruchel,et al.  Addition of Liposomal Daunorubicin (DaunoXome®) to FLAG Significantly Improves Treatment Response in Pediatric Relapsed AML: Final Results From the International Randomised Phase III Study Relapsed AML 2001/01. , 2009 .

[77]  S. Corey,et al.  Pediatric Therapy-related Myelodysplastic Syndrome/Acute Myeloid Leukemia: The MD Anderson Cancer Center Experience , 2009, Journal of pediatric hematology/oncology.

[78]  J. Feusner,et al.  Acute promyelocytic leukemia in childhood , 2009, Current oncology reports.

[79]  H. Caron,et al.  Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. , 2009, The Cochrane database of systematic reviews.

[80]  D. Reinhardt,et al.  International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia , 2009, British journal of haematology.

[81]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.

[82]  S. Raimondi,et al.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. , 2009, Blood.

[83]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[84]  S. Pileri,et al.  Myeloid sarcoma: extramedullary manifestation of myeloid disorders. , 2009, American journal of clinical pathology.

[85]  R. Hanada,et al.  Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  F. Lo‐Coco,et al.  Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[88]  S. Meshinchi,et al.  Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia , 2009, Clinical Cancer Research.

[89]  R. Pieters,et al.  Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. , 2009, Blood.

[90]  Joonhong Park,et al.  Three-way complex translocations in infant acute myeloid leukemia with t(7;12)(q36;p13): the incidence and correlation of a HLXB9 overexpression. , 2009, Cancer genetics and cytogenetics.

[91]  S. Raimondi,et al.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2009, Blood.

[92]  R. Pieters,et al.  Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML , 2009, Leukemia.

[93]  J. Merker,et al.  Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. , 2008, Blood.

[94]  E. Estey,et al.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2009, Blood.

[95]  G. Lyman,et al.  Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  A. Baruchel,et al.  Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia , 2008, British journal of haematology.

[97]  P. Veys,et al.  Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy , 2008, Bone Marrow Transplantation.

[98]  D. Reinhardt,et al.  Place of HSCT in treatment of childhood AML , 2008, Bone Marrow Transplantation.

[99]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  R. Tamminga,et al.  Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? , 2008, Haematologica.

[101]  C. Pui,et al.  Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis , 2008, Cancer.

[102]  C. Pui,et al.  Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia , 2008, Cancer.

[103]  K. Döhner,et al.  Molecular characterization of acute myeloid leukemia , 2008, Haematologica.

[104]  D. Reinhardt,et al.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. , 2008, Blood.

[105]  C. Pui,et al.  Current management and challenges of malignant disease in the CNS in paediatric leukaemia. , 2008, The Lancet. Oncology.

[106]  B. Druker,et al.  RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. , 2008, Blood.

[107]  G. Ehninger,et al.  MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. , 2008, Blood.

[108]  R. Schlenk,et al.  Significance of age in acute myeloid leukemia patients younger than 30 years , 2008, Cancer.

[109]  D. Liang,et al.  Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples , 2008, Leukemia.

[110]  S. Lipshultz,et al.  Anthracycline associated cardiotoxicity in survivors of childhood cancer , 2007, Heart.

[111]  R. Hanada,et al.  Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  P. Nathan,et al.  Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection , 2007, Annals of Internal Medicine.

[113]  R. Arceci,et al.  The incidence and clinical significance of nucleophosmin mutations in childhood AML. , 2007, Blood.

[114]  David A. Williams,et al.  Chemotherapy for myeloid malignancy in children with Fanconi anemia , 2007, Pediatric blood & cancer.

[115]  A. Hirt,et al.  The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG) , 2007, European journal of haematology.

[116]  S. Raimondi,et al.  Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. , 2007, Blood.

[117]  T. Taki,et al.  N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t(8;21) in Japan: a study of the Japanese childhood AML cooperative study group , 2007, Leukemia.

[118]  T. Haferlach,et al.  Insight into the molecular pathogenesis of myeloid malignancies , 2007, Current opinion in hematology.

[119]  F. Appelbaum.  Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission. , 2007, Best practice & research. Clinical haematology.

[120]  D. Reinhardt,et al.  Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12 , 2007, Leukemia.

[121]  D. Reinhardt,et al.  Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. , 2007, Blood.

[122]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[123]  G. Gustafsson,et al.  Improved outcome after relapse in children with acute myeloid leukaemia , 2007, British journal of haematology.

[124]  A. Holmes,et al.  Risk Factors for Acute Leukemia in Children: A Review , 2006, Environmental health perspectives.

[125]  T. Naoe,et al.  A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. , 2006, Blood.

[126]  R. Arceci,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[127]  F. Lo‐Coco,et al.  Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia. , 2007, Current topics in microbiology and immunology.

[128]  Bruce Greig,et al.  2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia , 2007, Cytometry. Part B, Clinical cytometry.

[129]  R. Larson.  Etiology and management of therapy-related myeloid leukemia. , 2007, Hematology. American Society of Hematology. Education Program.

[130]  J. Radich,et al.  Clinical implications of FLT3 mutations in pediatric AML. , 2006, Blood.

[131]  Hartmut Döhner,et al.  Acute myeloid leukaemia , 2006, The Lancet.

[132]  R. Pieters,et al.  High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9 , 2006, Genes, chromosomes & cancer.

[133]  Ursula Creutzig,et al.  Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  H. Dombret,et al.  Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.

[135]  E. Estey,et al.  Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. , 2006, Blood.

[136]  R. Arceci,et al.  Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  D. Johnston,et al.  Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  U. Creutzig,et al.  Pediatric acute myeloid leukemia: international progress and future directions , 2005, Leukemia.

[139]  R. Hills,et al.  Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials , 2005, Leukemia.

[140]  A. Baruchel,et al.  Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group , 2005, Leukemia.

[141]  Marcos González,et al.  Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  S. Meshinchi,et al.  Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia , 2005, Leukemia.

[143]  B. Falini,et al.  Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. , 2005, Blood.

[144]  D. Reinhardt,et al.  AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity , 2005, Leukemia.

[145]  R. Foà,et al.  GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. , 2005, Blood.

[146]  R. Scholten,et al.  Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. , 2005, European journal of cancer.

[147]  L. Leibovici,et al.  Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients , 2005, Annals of Internal Medicine.

[148]  S. Feig,et al.  Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era , 2005, Leukemia.

[149]  S. Orkin,et al.  Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1 , 2005, Nature Genetics.

[150]  J. Taub,et al.  Down syndrome, drug metabolism and chromosome 21 , 2005, Pediatric blood & cancer.

[151]  J. Downing,et al.  Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Materials and Methods , 2022 .

[152]  M. Loh,et al.  PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group , 2004, Leukemia.

[153]  U. Creutzig,et al.  Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  D. Reinhardt,et al.  Gemtuzumab Ozogamicin (Mylotarg®) in Children with Refractory or Relapsed Acute Myeloid Leukemia , 2004, Oncology Research and Treatment.

[155]  A. Baruchel,et al.  Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  D. de Jong,et al.  Spontaneous Remission in Congenital Leukemia is not Related to (Mosaic) Trisomy 21: Case Presentation and Literature Review , 2004, Pediatric hematology and oncology.

[157]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  C. Pui,et al.  Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience , 2003, Leukemia.

[159]  Augustin Ferrant,et al.  Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. , 2003, The New England journal of medicine.

[160]  G. Gustafsson,et al.  Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO‐AML trials , 2003, British journal of haematology.

[161]  A. Teigler‐Schlegel,et al.  Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement , 2003, Leukemia.

[162]  S. Scherer,et al.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. , 2003, Blood.

[163]  W. Tissing,et al.  Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. , 2003, Blood.

[164]  I. Baumann,et al.  A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases , 2003, Leukemia.

[165]  W. Hiddemann,et al.  Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  Bob Löwenberg,et al.  Acute myeloid leukemia and acute promyelocytic leukemia. , 2003, Hematology. American Society of Hematology. Education Program.

[167]  L. Oseth,et al.  Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML , 2002, Leukemia.

[168]  D. Gilliland,et al.  Molecular genetics of human leukemias: new insights into therapy. , 2002, Seminars in hematology.

[169]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[170]  A. Baruchel,et al.  Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  P. Voûte,et al.  Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[172]  S. Lipsitz,et al.  Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  R. Berger,et al.  Recurrence of OTT–MAL fusion in t(1;22) of infant AML‐M7 , 2002, Genes, chromosomes & cancer.

[174]  D. Reinhardt,et al.  Isolated Myelosarcoma in Children--Update and Review , 2002, Leukemia & lymphoma.

[175]  G. Peters,et al.  Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. , 2002, Blood.

[176]  H. Deeg,et al.  Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. , 2001, Blood.

[177]  D. Grimwade.  The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.

[178]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  S. Raimondi,et al.  Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  D. Reinhardt,et al.  Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children , 2001, Annals of Hematology.

[181]  C. Niemeyer,et al.  Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93 , 2001, Leukemia.

[182]  J. Buckley,et al.  A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.

[183]  J. Buckley,et al.  Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  J. Rossi,et al.  Good outcome of children with acute myeloid leukemia and t(8;21)(q22;q22), even when associated with granulocytic sarcoma , 2000, Cancer.

[185]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[186]  J. Esteve,et al.  A Modified AIDA Protocol With Anthracycline-Based Consolidation Results in High Antileukemic Efficacy and Reduced Toxicity in Newly Diagnosed PML/RAR-Positive Acute Promyelocytic Leukemia , 1999 .

[187]  R. Gray,et al.  A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial , 1999, British journal of haematology.

[188]  G. Henze,et al.  Definition of a standard‐risk group in children with AML , 1999, British journal of haematology.

[189]  K. Wheatley,et al.  Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial , 1999, Leukemia.

[190]  W. Kamps,et al.  Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel , 1998, European Journal of Pediatrics.

[191]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[192]  J. Boos,et al.  Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia , 1998, Leukemia.

[193]  C. Bloomfield,et al.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.

[194]  S. Lipshultz,et al.  Epidemiology of anthracycline cardiotoxicity in children and adults. , 1998, Seminars in oncology.

[195]  R. Gray,et al.  Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial , 1998 .

[196]  D. Grimwade,et al.  What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML Trial , 1997, Bone Marrow Transplantation.

[197]  A. Periclou,et al.  NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias , 1996, Cancer Chemotherapy and Pharmacology.

[198]  S. Bielack,et al.  Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? , 1996, European journal of cancer.

[199]  J. Buckley,et al.  Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. , 1996, Blood.

[200]  J. Krischer,et al.  Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood , 1996 .

[201]  A. Baruchel,et al.  Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). , 1996, Hematology and cell therapy.

[202]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[203]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[204]  J. Buckley,et al.  Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[205]  J. Ritter,et al.  Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[206]  E. Estey,et al.  Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  S. Raimondi,et al.  Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. , 1991, Blood.

[208]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[209]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[210]  P. Desai,et al.  Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. , 1990, Leukemia.

[211]  D. Miller,et al.  Acute lymphoblastic leukemia in children: an update of clinical, biological, and therapeutic aspects. , 1990, Critical reviews in oncology/hematology.

[212]  J. Ritter,et al.  Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia , 1987, Cancer.

[213]  M. Schell,et al.  Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. , 1987, The New England journal of medicine.

[214]  G. Dahl,et al.  Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia , 1978, Cancer.

[215]  R. Aur,et al.  Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. , 1977, The New England journal of medicine.